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One of the most serious consequences of cancer therapy is the development of a second
cancer, especially leukemia. Several distinct subsets of therapy-related leukemia can now be
distinguished. Classic therapy-related myeloid leukemia typically occurs 5 to 7 years after
exposure to alkylating agents and/or irradiation, has a myelodysplastic phase with trilineage
involvement, and is characterized by abnormalities of the long arms of chromosomes 5 and/or 7.
Response to treatment is poor, and allogeneic bone marrow transplantation is recommended.
Leukemia following treatment with agents that inhibit topoisomerase 11, however, has a shorter
latency, no preleukemic phase, a monoblastic, myelomonocytic, or myeloblastic phenotype, and
balanced translocations, most commonly involving chromosome bands 1 1q23 or 21q22. The
MLL gene at 1 1q23 or the AML1 gene at 21q22 are almost uniformly rearranged. MLL is involved
with many fusion gene partners. Therapy-related acute lymphoblastic leukemia also occurs with
1 1q23 rearrangements. Therapy-related leukemias with 1 1q23 or 21q22 rearrangements, inv(16)
or t(15;17), have a more favorable response to treatment and a clinical course similar to their
de novo counterparts. Environ Health Perspect 104(Suppl 6):1303-1307 (1996)
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Introduction
Therapy-related leukemia is a neoplastic
hematopoietic disorder arising in most cases
from a multipotent stem cell and in a few
cases from a lineage-committed progenitor.
The terms "therapy-related myelodysplastic
syndrome" (t-MDS) and "therapy-related
acute myeloid leukemia" (t-AML) are used
to describe a clinical syndrome that exhibits
important differences from AML that arises
de novo. The terms therapy-related or treat-
ment-relatedleukemia are descriptive and
are based on a patient's history ofexposure
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to cytotoxic agents. They imply a causal
relationship, but the mechanism remains
to be established. These terms may ulti-
mately be too restrictive, since the leukemia
that develops after exposure to benzene or
atomic bomb irradiation is similar or identi-
cal to the therapy-related leukemia syn-
drome. The term secondary leukemia
correctly denotes that the disease did not
develop spontaneously or de novo. However,
this term is often misunderstood as indicat-
ing merely that the leukemia occurred as the
second cancer in time or evolving from the
primary malignancy, and not necessarily
related to the treatment ofthe first cancer.
In the future, as various subtypes ofleuke-
mia are distinguished by specific genetic
alterations, the terms de novo (or primary)
and therapy-related leukemia will likely be
discarded and specific etiologies incorpo-
rated into thediagnostic nomenclature.
Mutations and
Leukemogenesis
The development of therapy-related
secondary neoplasms provides a unique,
ethically acceptable environment for study-
ing the effects ofmutagens on carcinogene-
sis in humans. Koeffler and Rowley (1)
have calculated that only 80 days would be
theoretically required from neoplastic
transformation of a single hematopoietic
stem cell to the emergence ofleukemia, ifa
cell doubling time of60 hr was assumed.
Typically, however, 5 to 7 years is required
for the emergence of a therapy-related
leukemia. Of note, 7 years was the mean
latency period for development ofleukemia
in survivors within 1500 m ofthe atomic
bomb blasts at Hiroshima and Nagasaki (2).
The long latency period characteristic of
therapy-related cancers after initial muta-
genic exposure suggests that "two hits" or
perhaps multiple intermediate steps are
required for full expression ofthe malignant
phenotype. It has not been possible to
determine whether the development of a
therapy-related neoplasm is a stochastic
event or whether certain individuals are at
higher risk (perhaps due to a DNA repair
deficiency or a heritable predisposition) and
thus might be identifiable in advance.
In general, two paths of investigation
have been explored. The first involves
meticulous clinical-pathologic and cytoge-
netic analysis of individual cases as they
present with therapy-related leukemia (3)
(Table 1). The second involves large-scale
epidemiological surveys of patients at
risk. There are now many such studies of
each type in the literature. Patients with
Hodgkin's disease were the first large cohort
ofrelatively uniformly treated patients who
experienced prolonged survival. After long-
term follow-up, hundreds of cases of
therapy-related leukemia have now been
reported on and analyzed (4). It soon
became clear that the risk oftherapy-related
leukemia was shared by patients with other
cancers and even nonmalignant disorders if
they had received cytotoxic treatment (5).
Investigators have sought to answer the fol-
lowing questions: Is the type ofchemother-
apy used important? Is radiation therapy
alone leukemogenic? Does radiotherapy
add to the risk from chemotherapy? Is the
age ofthe patient at the time oftreatment
an important risk factor? Is splenectomy a
risk factor? Is the risk of therapy-related
leukemia a function of the dose or the
duration ofchemotherapy administered? Is
the excess risk limited to a finite period
after treatment?
Classical Therapy-related
Leukemia
In the classic form of therapy-related
leukemia that follows treatment with alky-
lating agents and/or radiation therapy, the
blood and bone marrow findings resemble
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Table 1. Priortherapy, latency period, and clinical features oftherapy-related myeloid leukemia.
Priortreatment, n Latency, months Median age, No. ofpatients Progression of Median survival,
RT CT RT+CT Median Range range t-MDS t-AML t-MDStot-AML months Reference
8 25 22 48 12-131 62(22-75) 44 11 84%(median, 5months) 7 (30)
... .... ..
#?. ''.........1?|1'
11 21 31 56 10-192 55(6-76) 48 15 60% (median, 5months) 8.
2 7 66 34(from CR) - 55 20 73%(median, 7months) 4-10 (31)
10 29 37 6years 1-21 years 58(18-89) 29 47 57%(median,6months) 7 (32)
Abbreviations: RT, radiotherapy; CT, chemotherapy; CR, complete remission.
Table 2. Morphologic features of blood and bone marrow in classic alkylatortherapy-related myeloid leukemia.
Erythroid series Granulocytic series Megakaryocytic series
Peripheral blood Anemia, anisopoikilocytosis including Hypogranular neutrophils, hypolobulated Giant platelets, degranulated platelets,
teardrops, spherocytes and spiculated or hyperlobulated nuclei, nuclear thrombocytopenia, circulating
RBCs, nucleated RBCs, basophilic excrescences, pseudo-Pelger-Huet micromegakaryocytes, megakaryoblasts,
stippling, circulating erythroblasts, nuclei, basophilia, neutropenia, monocy- and megakaryocyte fragments
macrocytosis, polychromasia tosis, immature myeloid cells with blasts
appearing eventually, rarelyAuer rods
Bone marrow Erythroblasts, periodic acid-Schiff- Nuclear hyposegmentation, cytoplasmic Megakaryocytic hyperplasia with
positive normoblasts, dyserythro- hypogranulation atypical forms, micromegakaryocytes,
poiesis, erythroid hyperplasia with abnormal nuclear contours and sizes,
megaloblastoid features, ringed sider- Widely spaced nuclear lobes, mononu-
oblasts, nuclear budding, karyorrhexis, clearforms, giantcompound granules,
binuclearity, nuclear bridging hypogranularcytoplasm
those seen in the primary myelodysplastic
syndromes (Table 2). Anemia and throm-
bocytopenia are extremely common.
Leukopenia may also be present. Marked
dysplastic changes are observed in all three
cell lines. Early in the course ofdisease, red
cell poikilocytosis may be particularly
notable in the peripheral blood film (6).
The bone marrow may have variable cellu-
larity, but is most often hypercellular.
Hypocellular and even aplastic marrows are
seen in some cases. Mild to marked retic-
ulin fibrosis may be present. The degree of
dysgranulopoiesis and dysmegakaryocy-
topoiesis is typically greater than that
observed in primary MDS. Many cases of
therapy-related leukemia are not easily clas-
sified by the French-American-British
Cooperative Group criteria used for either
primary MDS or AML de novo (3,7).
When attempts have been made to do so,
refractory anemia with excess blasts and
refractory anemia with excess blasts in
transformation are most common.
About two-thirds of patients present
with fewer than 30% blast cells in the
marrow and <5% blasts in the blood, and
therefore, these patients have been diag-
nosed as t-MDS. However, unlike primary
MDS, which may have a long preleukemic
phase, patients with therapy-related
leukemia have a more prominent arrest of
hematopoietic maturation and more rapidly
accumulate >30% marrow blasts. Typically,
the t-MDS phase lasts for about 6 months
(3,7). As these cases evolve to more overt
leukemia, features characteristic of FAB
subtypes MI, M2, or M4 are most
common. However, there are difficulties in
classifying therapy-related leukemia
according to the FAB criteria designed for
AML de novo because most cases demon-
strate trilineage involvement and often
overlap several subtypes. Auer rods are
rarely seen, and myeloperoxidase and non-
specific esterase reactivity are often only
weakly expressed.
There is a continuum ofclonal expan-
sion and dedifferentiation that occurs in the
neoplastic clone and subclones that overlaps
the quantitative categories ofMDS, AML,
and chronic myeloproliferative disorders.
Classic t-AML is often not rapidly progres-
sive, but it is relatively refractory to conven-
tional chemotherapy (8). Severe and
life-threatening pancytopenia are observed
in each stage ofthe disease. Shortened sur-
vival is more a function offailure ofnormal
bone marrow hematopoiesis rather than
rapid accumulation ofbone marrow blast
cells. Allogeneic bone marrow transplanta-
tion is recommended when possible.
Clonal chromosomal abnormalities,
often ofa complex nature, are identified in
most cases of classical therapy-related
leukemia (3,9-12). Loss ofpart or all of
chromosomes 5 and/or 7 are the character-
istic findings, and have been reported in
almost 90% of cases in some series (3).
Table 3 shows the distribution ofcytoge-
netic abnormalities observed in 240
patients with therapy-related leukemia
studied at the University ofChicago. The
most common single abnormality is mono-
somy 7, followed in frequency by deletion
ofthe long arm ofchromosome 5 [del(5q)]
and by monosomy 5. These same abnor-
malities are observed in primary MDS and
AML de novo, especially in older patients
Table 3. Cytogenetic abnormalities in therapy-related
myeloid leukemia (University ofChicago series).
No. ofpatients 240
No. with clonal abnormalities 218(91%)
Abnormalities ofchromosomes 5 and/or7 163 (69%)
Chromosome 5 only 38 (16%)
Chromosome 7 only 71 (30%)
Chromosomes 5 and 7 54(23%)
t(l1q23) 7 (3%)
t(3;21) 3 (1%)
t(8;21) 2(1%)
t(l5;17) 3(1%)
+8 10(4%)
Other abnormalities 30(13%)
Data from MM LeBeau (unpublished data).
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and those with occupational exposure to
potential carcinogens. Their frequency,
however, is clearly higher in therapy-
related leukemia. Recent molecular investi-
gation has focused on identifying a
putative leukemia suppressor gene in chro-
mosome band 5q31, a critical region that is
consistently deleted in leukemia cells with
5q abnormalities (3).
Leukemia Following
Topoisomerase 11 Inhibitors
Whereas classic t-AML is characterized by
abnormalities involving the long arms of
chromosomes 5 and/or 7, the leukemias
secondary to agents that target topo-
isomerase II result in translocations involv-
ing chromosome 11, band q23, and less
commonly, chromosome 21, band q22
(11,13-19). In contrast to classic t-AML,
these leukemias have a much shorter
latency between initiation ofchemotherapy
for the primary cancer and the develop-
ment ofleukemia (Table 4). In addition, a
preceding myelodysplastic syndrome is not
associated with these leukemias. The 11q23
cases primarily have monoblastic (M5) or
myelomonocytic (M4) phenotypes, but
cases ofAML-M1 and M2 as well as acute
lymphoblastic leukemia (ALL) have been
described. The 21q22 cases are typically
AML M2 (19,20). The response to chemo-
therapy in this newer syndrome oftherapy-
related leukemia also differs from classic
t-AML and is more favorable.
A consistent pattern has emerged of
prior treatment with inhibitors oftopoiso-
merase II either alone or in combination
with alkylating agents. At first, the associa-
tion was linked only to the epipodophyllo-
toxins, etoposide, and teniposide (16,17).
However, subsequent reports have also
implicated DNA intercalating agents such
as doxorubicin, 4-epi-doxorubicin, mitox-
antrone, and actinomycin D (18,21).
The Role of 11q23
Translocations
Chromosome 11q23 translocations occur
in both de novo and therapy-related
leukemia. These translocations affect 7 to
10% of patients with ALL de novo, with
the t(4;I 1)(q21;q23) and the t(11;19)
(q23;pl3.3) predominating, and 5-6% of
AML de novo with t(6;1 1)(q27;q23),
t(9;11)(p22;q23), and t(11;19)(q23;p13.1)
being the most common. TheALL patients
are usually FAB Li, but in addition to the
usual B-cell markers, they often express
myeloid or monocytoid markers. The
AML patients are typically myelomono-
cytic (M4) or monoblastic (M5) and often
coexpress lymphoid markers. In both AML
and ALL with 1 q23 translocations, the
patients often present with hyperleukocy-
tosis and early central nervous system
involvement. The clinical presentation,
morphology, and immunophenotype of
therapy-related leukemias with 1 1q23
translocations are indistinguishable from
de novo cases.
Therapy-related Acute
Lymphoblastic Leukemia
The classic syndrome of therapy-related
leukemia with aberrations involving chro-
mosomes 5 and 7 has exclusively involved
the myeloid lineage. The initial case reports
of therapy-related leukemia with 1 1q23
translocations, predominantly with the
t(9;11), were also myeloid leukemias, albeit
usually of a monoblastic phenotype (17).
However, given the involvement of 11q23
in both myeloid and lymphoblastic acute
leukemias that occur de novo, it should not
be surprising that therapy-related lym-
phoblastic leukemias have also been
described. In 1985 Secker-Walker et al.
(22) reported on a child with neuroblas-
toma who was treated with a multi-drug
regimen that included doxorubicin and
teniposide; ALL with a t(4;11) developed
12 months after completion of therapy
(22). In 1988 Archimbaud et al. (23)
reported on the development ofALL with
a t(4;11) in two breast cancer patients
treated with doxorubicin-containing regi-
mens. Several other cases oftherapy-related
ALL have been described since that time. In
an interesting recent report byJonveaux et
al. (24), a patient initially treated for an
acute monoblastic leukemia de novo with a
t(6;11)(q27;q23), subsequently developed
ALL with a t(4;1 1) (24). Different MLL
gene rearrangements were present in the
leukemia cells at each presentation. Whereas
the incidence ofALL de novo with 1 1q23
translocations exceeds that ofAML de novo
with 11q23 translocations, the ratios are
clearly reversed in the therapy-related set-
ting. This may reflect the increased cycling
of myeloid precursor cells following
chemotherapy. Nevertheless, therapy-related
leukemia should not be considered an exclu-
sivelymyeloidmalignancy.
The role of other cofactors besides
cytotoxic agents in the formation of ther-
apy-related leukemia is unknown. An
interim analysis of data from a recent
National Surgical Adjuvant Breast Project
trial (NSABP-B25) of intensive adjuvant
chemotherapy for breast cancer revealed
five cases of t-AML out of2548 patients
treated. All cases were either FAB M4 or
M5 and had short latency periods. Two
cases were found to have 11q23 abnormali-
ties. There were three arms to this trial; all
patients received four monthly courses
with doxorubicin plus cyclophosphamide
at one ofthree higher-than-standard doses.
All groups received filgrastim (G-CSF) to
ameliorate neutropenic toxicities. The rapid
appearance offive cases of t-AML in this
trial prompted a clinical alert from the
National Cancer Institute. Earlier descrip-
tions of t-AML with 11q23 abnormalities
Table 4. Contrasting features oftherapy-related leukemia secondary to eitheralkylating agents ortopoisomerase 11 inhibitors.
Response to
Chromosome Preleukemia FAB induction Long-term
abnormality phase morphology Latency chemotherapy survival Chemotherapy drugs
Alkylating agents del(5q), -5 Myelodysplastic Notclassifiable 5-7 years Poor Poor Melphalan, mechlorethamine,
del(7q), -7 syndrome by current criteria chlorambucil, cyclophosphamide,
carmustine, lomustine semustine
procarbazine, dacarbazine,
mitolactol
Topoisomerase 11q23translocations, None Usually M4, 6 months- Good Poor Etoposide, teniposide,
11 inhibitor 21q22 translocations M5; some Ml, 5years actinomycin D, doxorubicin,
M2 and ALL-Li 4-epi-doxorubicin, mitoxantrone
Various agents t(l5;17) None M3 2-3 years Good Good Bimolane
inv(l6) None M4Eo <3 years Good Good
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predated the widespread use ofhematopoi-
etic growth factors. The unexpected rate of
t-AML in this trial has raised the concern
that growth factors may be synergistic with
chemotherapy in inducing t-AML. How-
ever, no data outside of this trial exist yet
to examine this issue further.
Different Genetic Mechanisms
for Leukemogenesis
The particular mechanisms ofDNAdamage
that lead either to chromosomal deletions
or to balanced translocations may underlie
the differences in latencies between the two
forms oftherapy-related leukemia (15). In
the case of chromosomal deletions, one
allele ofa putative tumor-suppressor gene
may be inactivated. Before the affected cell
would gain a proliferative advantage, how-
ever, the second allele would also have to
be deleted or mutated. Additionally, losses
ofboth alleles ofan individual tumor sup-
pressor may not be sufficient to confer a
malignant phenotype. As described in the
model ofcolorectal tumorigenesis, multiple
tumor-suppressor genes or oncogenes may
need to be mutated to ultimately transform
a cell. This series ofgenetic changes may
require an extended period of time, thus
explaining the long latency ofalkylator-
induced t-AML. In contrast, balanced
chromosome translocations result in the
activation ofcellular oncogenes in a domi-
nant fashion. These rearrangements, such
as those involving the MLL gene at 11q23,
mayyield a fusion gene that acts as a domi-
nant oncogene. Whereas this fusion gene
alone may not be sufficient to transform an
hematopoietic progenitor cell, relatively
fewer genetic events may be required to
proceed to the leukemic phenotype. In line
with this hypothesis, 70 to 80% ofall acute
leukemias de novo in infants, both lym-
phoid and myeloid, involve the MLL gene.
Moreover, these cases have even been
reported in the neonatal period. Thus,
11 q23 translocations can clearly induce the
formation ofleukemia over a short interval
of time. The striking incidence of MLL
gene rearrangements in infant leukemias
suggests a potential genetic susceptibility to
translocations at this locus. Ifthis were the
case, perhaps only certain patients with an
as-yet unknown DNA repair deficiency
might be susceptible to the mutagenic
effect oftopoisomerase II inhibitors.
MLL Gene in Chromosome
Band 11q23
Because of the different phenotypes and
the large number ofrecurring chromosomal
aberrations involving 1 1q23, a major
question in the field of cancer molecular
genetics had been whether one or several
oncogenes at that locus might be impli-
cated in the pathogenesis ofthese hemato-
logic malignancies. Rowley and co-workers
(25) were able to identify a gene that spans
the 1 lq23 breakpoint region and named it
MLL for myeloid-lymphoid leukemia or
mixed lineage leukemia gene. Several other
groups have also cloned the same gene and
assigned it names such as ALL-1, HRX, and
H-trx. The MLL gene has multiple large
transcripts with an open reading frame of
11.7 kb and codes for a predicted protein of
431 kDa. At its amino terminus, MLL
contains an AT hook domain that has been
shown to bind to cruciform DNA (26).
There are two regions with ahigh homology
to the Drosophila trithoraxgene. The first is
a series ofzinc fingers immediately 3' to the
breakpoint region, and the second region is
at the carboxyl terminus and shows an
extremely high level ofevolutionary conser-
vation. Although the functions of MLL
remain unknown, these motifs suggest that
it maybe acting as a transcription factor.
To address the question ofMLL involve-
ment in hematologic malignancies with
diverse 11q23 translocations, we studied
patients with either AML, ALL, or non-
Hodgkin's lymphoma (27). MLL gene
rearrangements were detected in 58 ofthe
61 leukemia patients and in 3 ofthe 20 lym-
phoma patients. This included all patients
with the five common 1lq23 translocations
mentioned earlier plus 16 uncommon
1lq23 rearrangements that involved the
MLL gene, for a total of21 different chro-
mosomal abnormalities that affect the MLL
gene. All ofthe breaks occurred in an 8.3-kb
pairgenomic BamHI fragment.
Several genes at breakpoints on the
partner chromosomes involved in 1 lq23
translocations have been cloned. These
include AF-4 in the t(4; 11)(q21;q23),
ENL in the t(l1;19)(q23;p13.3), AF-9 in
the t(9;11)(p22;q23), AF-6in the t(6;11)
(q27;q23), AF-lp in the t(I;1 l)(p32;q23),
AF-I0 in the t(1O;11)(pl2;q23), AF-17in
the t(l7;11)(q21 ;q23), and AF-X in the
t(X;1 1)(q13;q23). The functions of these
genes have not yet been determined.
Thirman et al. (28) recently cloned the
gene ELL that fuses to MLL in the t(I1;19)
(q23;p13.1), a recurring abnormality in
AML as well as one of the most common
breakpoints in topoisomerase II induced
t-AML (28). This translocation is distinct
from another type of 11;19 translocation
with a 19pl3.3 breakpoint that results in
the fusion of MLL to the ENL gene. ELL
is not homologous to other MLL partner
genes. Because 11q23 translocations always
result in the generation ofin-frame fusion
transcripts, the sequences contributed
from these partner genes may be essential
to leukemogenesis.
The AMLI gene at chromosome band
21q22 also fuses to genes at multiple chro-
mosomal breakpoint regions, albeit many
fewer than MLL (19,20). Nucifora and co-
workers (19,20,29) have identified com-
plex intergenic splicing between the AMLI
gene and either EAP, MDSI, or EVII
within chromosome band 3q26 in the
t(3;21). AMLI also fuses with ETO at
8q22 in the t(8;21) in both de novo and
therapy-related cases.
Conclusions
As the numbers ofcancer survivors increase
after conventional cytotoxic treatment, the
incidence oftherapy-related leukemia will
undoubtedly rise. It is imperative that the
leukemogenic potential of current multi-
agent treatment regimens for malignant
and nonmalignant disorders be considered
prospectively in primary treatment plan-
ning and be reduced, ifpossible. As further
understanding about mechanisms ofmuta-
genesis accumulates, it is likely that certain
individuals who have increased susceptibil-
ity to the leukemogenic activity ofparticu-
lar agents can be identified. Prevention of
this complication of cancer treatment is a
clinical and scientific challenge, but it is
clearly the appropriate goal.
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